Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30997647 | 1.00 | TSHR (0.49) | TSHRSMN1; SMN2DRD4OPRM1CYP2C19 | |
| SCHEMBL1399548 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2OPRM1CYP2C19KDM4ECYP2D6 | |
| SCHEMBL27792254 | 0.79 | TSHR (0.34) | TSHRSMN1; SMN2DRD4OPRM1CYP2C19 | |
| SCHEMBL4055295 | 0.76 | ALDH1A1 (0.43) | TSHRSMN1; SMN2CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL31055020 | 0.76 | CYP1A2 (0.34) | TSHRSMN1; SMN2CYP1A2CYP2D6MAPK1 | |
| SCHEMBL29932100 | 0.74 | ATM (0.42) | TSHRCYP2C19CYP3A4CYP1A2MAPK1 | |
| SCHEMBL1752645 | 0.72 | KDM1A (0.50) | TSHRCYP2C19KDM4ECYP3A4CYP1A2 | |
| SCHEMBL1829575 | 0.72 | KDM1A (0.46) | TSHRSMN1; SMN2CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL30730934 | 0.71 | ACHE (0.42) | SMN1; SMN2KDM4E | |
| SCHEMBL12908060 | 0.70 | ALDH1A1 (0.63) | TSHRSMN1; SMN2CYP2C19CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | TSHR 4264/4885SMN1; SMN2 4134/4885DRD4 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.